<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03691415</url>
  </required_header>
  <id_info>
    <org_study_id>CMO-EPI-FAS-0537</org_study_id>
    <secondary_id>EUPAS23762</secondary_id>
    <nct_id>NCT03691415</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Effectiveness of BELKYRA® Inj. for the Treatment of Patients With Submental Fullness Due to Submental Fat: A Postmarketing Surveillance Study in Korea</brief_title>
  <official_title>Evaluation of the Safety and Effectiveness of BELKYRA® Inj. for the Treatment of Patients With Submental Fullness Due to Submental Fat: A Post Marketing Surveillance Study in Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this PMS study is to evaluate the safety and effectiveness of BELKYRA Inj.&#xD;
      used according to the dose specified in the instructions for use, for the treatment of&#xD;
      patients with SM fullness due to SMF, through active investigation under routine clinical&#xD;
      practice&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study discontinued due to business decisions.&#xD;
  </why_stopped>
  <start_date type="Actual">September 7, 2018</start_date>
  <completion_date type="Actual">April 14, 2020</completion_date>
  <primary_completion_date type="Actual">April 14, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)</measure>
    <time_frame>Baseline, Follow up visit (within 3 months of injection)</time_frame>
    <description>A validated scale used by investigators to assess SM convexity/amount of SMF. Specifically, the CR-SMFRS ranges in whole number increments from 0 (absent submental convexity) to 4 (extreme submental convexity)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Patient-Reported Submental Fat Rating Scale (PR-SMFRS)</measure>
    <time_frame>Baseline, Follow up visit (within 3 months of injection)</time_frame>
    <description>Validated scale used by patients to evaluate SM size. Specifically, the PR-SMFRS asks patients to assess how much fat they have under their chins by selecting options ranging from &quot;no chin fat at all&quot; to &quot;a very large amount of chin fat&quot;.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">71</enrollment>
  <condition>Submental Fullness</condition>
  <arm_group>
    <arm_group_label>BELKYRA Inj.</arm_group_label>
    <description>Each patient will be administered BELKYRA Inj. at least once and the interval between treatments not less than 1 month apart and follow-up within 3 months of the last treatment session.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BELKYRA Inj.</intervention_name>
    <description>Patient will be administered BELKYRA Inj. at least once and the interval between treatments not less than 1 month apart.</description>
    <arm_group_label>BELKYRA Inj.</arm_group_label>
    <other_name>Deoxycholic acid</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study will include adult patient is an adult (≥ 18 years of age) in South Korea&#xD;
        treated with BELKYRA for the improvement of moderate to severe convexity or fullness&#xD;
        associated with submental fat in adults&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eligible and consenting Korean patients&#xD;
&#xD;
          -  Patients who have consented to the study and who have signed the private information&#xD;
             protection act form or ICF&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients having infection at the infection sites&#xD;
&#xD;
          -  Patients presenting evidence of causes of enlarged submental area other than localized&#xD;
             submental fat (E.g.: thyroid enlargement, enlarged submental salivary glands, cervical&#xD;
             lymphadenopathy, etc.)&#xD;
&#xD;
          -  Patients participating in an interventional clinical study, currently or within 30&#xD;
             days before enrollment, will not be eligible for inclusion in the study&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Renal impairment patients&#xD;
&#xD;
          -  Hepatic impairment patients&#xD;
&#xD;
          -  Patients with severe laxity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzanne St. Rose, DVM, MSc, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oracle-Dermatology</name>
      <address>
        <city>Daejeon</city>
        <zip>35234</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Goldenview plastic surgery</name>
      <address>
        <city>Seoul</city>
        <zip>06010</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Apgujeong) Oracle-Dermatology</name>
      <address>
        <city>Seoul</city>
        <zip>06022</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dream-Dermatology</name>
      <address>
        <city>Seoul</city>
        <zip>06030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.allerganclinicaltrials.com/</url>
    <description>Additional information on study locations near you may be found at AllerganClinicalTrials.com. For any study not on AllerganClinicalTrials.com, please contact IR-CTRegistration@Allergan.com for assistance.&quot;</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 28, 2018</study_first_submitted>
  <study_first_submitted_qc>September 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2018</study_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Double Chin Fat Reduction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deoxycholic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

